CGEM ▲ +0.8% - Cullinan Therapeutics, Inc. $CGEM - Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Cullinan Therapeutics gained 0.8% today ahead of a virtual analyst and investor event featuring Phase 3 REZILIENT3 data for its lead candidate zipalertinib combined with chemotherapy, which is being presented at the IASLC 2026 World Conference on Lung Cancer. The company is hosting the event to discuss results from this late-stage trial in a key indication, potentially providing investors with updated efficacy and safety information for the combination therapy. 14-SEP-2026 07:00 AM ET